NCT02629289View on ClinicalTrials.gov

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Neutropenia

Interventions

DRUG

HSP-130

DRUG

US-approved Neulasta

DRUG

EU-approved Neulasta

Trial Locations (1)

5000

CMAX (a Division of IDT Australia Limited), Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Pfizer

INDUSTRY